Evolus Expands Strategic Partnership to Commercialize Estyme in Canada, Australia, and New Zealand

Evolus expanded its partnership with Symatese to gain exclusive rights to commercialize the Estyme injectable HA gel collection in Canada, Australia, and New Zealand, realizing a consistent multi-product platform alongside Jeuveau. This strategic expansion strengthens its international competitive positioning to address a combined $500 million market opportunity.